A Agilent Technologies Inc.

Agilent Receives Award for Sustainability Leadership

Agilent Technologies Inc. (NYSE: A) has received an award for leadership in advancing environmental sustainability from the Business Intelligence Group. The award recognizes Agilent’s sustainability efforts across all its operations and through all its products and services, which are used in more than 265,000 labs worldwide.

recognize organizations that have made sustainability an integral part of their business practice or overall mission. Agilent’s environmental initiatives are closely linked to the company’s mission of advancing the quality of life.

“We’re extremely pleased to be recognized by the Business Intelligence Group for our work in sustainability,” said Neil Rees, vice president and head of ESG Programs. “For Agilent, sustainability and improving the environment are part of who we are and what we do every day.”

Since 2014, Agilent has reduced carbon emissions intensity per square foot by 34 percent, reduced municipal water intensity per square foot by 22 percent, and diverted 94 percent of solid waste from landfills. The company has also committed to achieving net-zero greenhouse gas emissions by 2050, which includes an interim goal of reducing Scope 1 and 2 emissions by 50 percent and Scope 3 emissions by 30 percent by 2030 (from a 2019 baseline).

Agilent is also helping lab customers around the world achieve their environmental goals. Labs consume 5 to 10 times more energy and water than typical offices and discard 12 billion pounds of plastic annually. In Agilent’s 2019 lab manager survey, 87% reported that sustainability goals—from reducing energy and water consumption to cutting emissions and purchasing green products—figure prominently in their lab operations.

To help customers reach their sustainability goals, Agilent designs many of its products to use less energy and produce less direct waste than other options. For example, Agilent’s Intuvo 9000 Gas Chromatography System uses an efficient direct heating system that requires less than half the electrical power of a conventional gas chromatography while also reducing the heat energy emitted back into the lab.

To reduce waste, Agilent’s enables customers to trade in their used analytical instrument for cash or toward the purchase of a new instrument. Customers can also return select decommissioned instruments to Agilent for recycling. In fiscal year 2021, Agilent bought back 900 used instruments from customers, sold over 3,500 certified pre-owned instruments, and took back 2,000 instruments through the program.

Agilent’s digital services allow labs to operate more efficiently through automation, artificial intelligence, and virtual support. Agilent also labels many of its instruments with the , which indicates the environmental footprint of the instrument. Agilent is a leader in developing environmental lab practices—the company recently announced that its customer demonstration lab received the , the gold standard in laboratory sustainability practices. These initiatives also advance Agilent’s commitment to achieving .

Read more about Agilent’s sustainability efforts on .

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.32 billion in fiscal 2021 and employs 17,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on , and .

EN
07/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch